Related Experiment Video

Updated: Jun 24, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with

Chia-Chi Lin1, Chih-Hsin Yang

  • 1Department of Oncology, National Taiwan University Hospital, 7 Chung-Shan S Rd., Taipei, 10002, Taiwan.

Targeted Oncology
|April 4, 2009
PubMed

Insights

Elderly and frail patients with advanced non-small cell lung cancer (NSCLC) may benefit from EGFR tyrosine kinase inhibitors (TKIs) like erlotinib and gefitinib, offering an alternative to traditional chemotherapy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Elderly and poor performance status patients with advanced non-small cell lung cancer (NSCLC) often experience poor tolerance to conventional chemotherapy.
  • Novel therapeutic strategies are required for these vulnerable patient populations.

Purpose of the Study:

  • To review the efficacy and safety of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), specifically erlotinib and gefitinib.
  • To summarize the outcomes of phase II trials investigating EGFR TKIs in elderly or poor performance status patients with advanced NSCLC.

Main Methods:

  • Systematic review of published phase II clinical trials.
  • Analysis of data concerning erlotinib and gefitinib in specific NSCLC patient subsets.

Main Results:

  • EGFR TKIs demonstrate activity in advanced NSCLC patients with poor performance status or elderly status.
  • Results from phase II trials indicate potential benefits in these challenging patient groups.

Conclusions:

  • Erlotinib and gefitinib represent viable treatment options for elderly and poor performance status patients with advanced NSCLC.
  • Further investigation into optimal use within these populations is warranted.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...